J&J is paying $31 for each Mentor share, a 92% premium to Friday's closing price. The stock traded above $31 as recently as June.
While most of Mentor's sales are from breast implants -- the company focuses on reconstruction for cancer patients, Mentor is awaiting word from the Food and Drug Administration for face fillers, the market for wrinkle treatment now dominiated by Botox.
Mentor, which will become part of J&J's Ethicon surgical-products business, is expected to cut J&J's 2009 earnings by about 3 cents to 5 cents a share. Analysts were expecting $4.67.
The deal, set to close in the first quarter, comes a week after JNJ said it agreed to buy Omrix Biopharmaceuticals Inc. (OMRI) for about $438 million, giving J&J full access to products which control bleeding during surgery.
-- Mike Barris, Dow Jones Newswires
Family Travel: The New Perks http://www.smartmoney.com/spending/travel/family-travel-the-new-perks/?cid=1122
Your Own Winter Olympics at SmartMoney.com: With curling broom and bobsled helmet in hand, we play Olympian at a f... http://bit.ly/bJH03I
Are the New DIY Credit Cards a Good Deal at SmartMoneycom http://bit.ly/9AvIK0
Are the New DIY Credit Cards a Good Deal at SmartMoneycom: Issuers want you to think you can choose your finance t... http://bit.ly/96IfRW
UPDATE: Baidu Profit Up 48%; Issues Strong 1Q Guidance: (Source: DJON) http://bit.ly/dCbxOz http://nzpis.co.nz